vs
Amphastar Pharmaceuticals, Inc.（AMPH）とINTERNATIONAL BANCSHARES CORP（IBOC）の財務データ比較。上の社名をクリックして会社を切り替えられます
INTERNATIONAL BANCSHARES CORPの直近四半期売上が大きい（$217.7M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.2倍）。INTERNATIONAL BANCSHARES CORPの純利益率が高く（62.3% vs 13.3%、差は49.0%）。INTERNATIONAL BANCSHARES CORPの前年同期比売上増加率が高い（4.5% vs -1.8%）。INTERNATIONAL BANCSHARES CORPの直近四半期フリーキャッシュフローが多い（$472.9M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 2.8%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
インターナショナル・バンクシェアーズ・コーポレーションは米国テキサス州ラレドを本拠地とする銀行持株会社で、主要子会社はインターナショナル・バンク・オブ・コマースです。傘下の銀行子会社を通じて217の営業店舗と315台のATMを運営し、テキサス州とオクラホマ州にある88のコミュニティに金融サービスを提供しています。
AMPH vs IBOC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $217.7M |
| 純利益 | $24.4M | $106.9M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 62.8% |
| 純利益率 | 13.3% | 62.3% |
| 売上前年比 | -1.8% | 4.5% |
| 純利益前年比 | -35.7% | -7.1% |
| EPS（希薄化後） | $0.51 | $1.71 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $217.7M | ||
| Q3 25 | $191.8M | $218.1M | ||
| Q2 25 | $174.4M | $208.2M | ||
| Q1 25 | $170.5M | $198.2M | ||
| Q4 24 | $186.5M | $208.3M | ||
| Q3 24 | $191.2M | $211.8M | ||
| Q2 24 | $182.4M | $207.8M | ||
| Q1 24 | $171.8M | $205.8M |
| Q4 25 | $24.4M | $106.9M | ||
| Q3 25 | $17.4M | $108.4M | ||
| Q2 25 | $31.0M | $100.1M | ||
| Q1 25 | $25.3M | $96.9M | ||
| Q4 24 | $38.0M | $115.1M | ||
| Q3 24 | $40.4M | $99.8M | ||
| Q2 24 | $37.9M | $97.0M | ||
| Q1 24 | $43.2M | $97.3M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 62.8% | ||
| Q3 25 | 13.2% | 62.6% | ||
| Q2 25 | 24.2% | 60.5% | ||
| Q1 25 | 21.9% | 61.1% | ||
| Q4 24 | 24.2% | 64.2% | ||
| Q3 24 | 29.8% | 60.0% | ||
| Q2 24 | 30.3% | 60.1% | ||
| Q1 24 | 27.9% | 59.9% |
| Q4 25 | 13.3% | 62.3% | ||
| Q3 25 | 9.0% | 49.7% | ||
| Q2 25 | 17.8% | 48.1% | ||
| Q1 25 | 14.8% | 48.9% | ||
| Q4 24 | 20.4% | 71.5% | ||
| Q3 24 | 21.1% | 47.1% | ||
| Q2 24 | 20.8% | 46.7% | ||
| Q1 24 | 25.1% | 47.3% |
| Q4 25 | $0.51 | $1.71 | ||
| Q3 25 | $0.37 | $1.74 | ||
| Q2 25 | $0.64 | $1.61 | ||
| Q1 25 | $0.51 | $1.56 | ||
| Q4 24 | $0.74 | $1.85 | ||
| Q3 24 | $0.78 | $1.60 | ||
| Q2 24 | $0.73 | $1.56 | ||
| Q1 24 | $0.81 | $1.56 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $5.5B |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $3.3B |
| 総資産 | $1.6B | $16.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $5.5B | ||
| Q3 25 | $276.2M | $5.6B | ||
| Q2 25 | $231.8M | $5.8B | ||
| Q1 25 | $236.9M | $5.6B | ||
| Q4 24 | $221.6M | $5.4B | ||
| Q3 24 | $250.5M | $5.8B | ||
| Q2 24 | $217.8M | $5.7B | ||
| Q1 24 | $289.6M | $5.7B |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $3.3B | ||
| Q3 25 | $776.7M | $3.1B | ||
| Q2 25 | $757.5M | $3.0B | ||
| Q1 25 | $751.3M | $2.9B | ||
| Q4 24 | $732.3M | $2.8B | ||
| Q3 24 | $727.7M | $2.7B | ||
| Q2 24 | $713.3M | $2.6B | ||
| Q1 24 | $672.4M | $2.5B |
| Q4 25 | $1.6B | $16.6B | ||
| Q3 25 | $1.7B | $16.6B | ||
| Q2 25 | $1.6B | $16.5B | ||
| Q1 25 | $1.6B | $16.3B | ||
| Q4 24 | $1.6B | $15.7B | ||
| Q3 24 | $1.5B | $15.9B | ||
| Q2 24 | $1.5B | $15.5B | ||
| Q1 24 | $1.6B | $15.4B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $491.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $472.9M |
| FCFマージンFCF / 売上 | 13.4% | 217.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 8.3% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 4.59× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $809.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $491.1M | ||
| Q3 25 | $52.6M | $115.2M | ||
| Q2 25 | $35.6M | $95.5M | ||
| Q1 25 | $35.1M | $140.5M | ||
| Q4 24 | $29.0M | $473.9M | ||
| Q3 24 | $60.0M | $116.5M | ||
| Q2 24 | $69.1M | $107.2M | ||
| Q1 24 | $55.3M | $135.4M |
| Q4 25 | $24.6M | $472.9M | ||
| Q3 25 | $47.2M | $112.2M | ||
| Q2 25 | $25.0M | $91.6M | ||
| Q1 25 | $24.4M | $133.1M | ||
| Q4 24 | $16.6M | $459.8M | ||
| Q3 24 | $46.2M | $109.6M | ||
| Q2 24 | $63.1M | $104.9M | ||
| Q1 24 | $46.5M | $128.9M |
| Q4 25 | 13.4% | 217.2% | ||
| Q3 25 | 24.6% | 51.5% | ||
| Q2 25 | 14.3% | 44.0% | ||
| Q1 25 | 14.3% | 67.1% | ||
| Q4 24 | 8.9% | 220.8% | ||
| Q3 24 | 24.1% | 51.7% | ||
| Q2 24 | 34.6% | 50.5% | ||
| Q1 24 | 27.1% | 62.6% |
| Q4 25 | 4.5% | 8.3% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 6.1% | 1.9% | ||
| Q1 25 | 6.3% | 3.7% | ||
| Q4 24 | 6.7% | 6.8% | ||
| Q3 24 | 7.2% | 3.3% | ||
| Q2 24 | 3.3% | 1.1% | ||
| Q1 24 | 5.1% | 3.2% |
| Q4 25 | 1.35× | 4.59× | ||
| Q3 25 | 3.03× | 1.06× | ||
| Q2 25 | 1.15× | 0.95× | ||
| Q1 25 | 1.39× | 1.45× | ||
| Q4 24 | 0.76× | 4.12× | ||
| Q3 24 | 1.48× | 1.17× | ||
| Q2 24 | 1.82× | 1.11× | ||
| Q1 24 | 1.28× | 1.39× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IBOC
セグメントデータなし
